Abstracts tagged "Abatacept"

Abstract Number: 628 • 2016 ACR/ARHP Annual Meeting
Analysis of Baseline Characteristics of Rheumatoid Arthritis Patients Treated with Abatacept Compared to Those Treated with Tumor Necrosis Factor Inhibitors in Clinical Practice
M. Victoria Hernández¹, Carlos Sánchez-Piedra², Juan D. Cañete¹, Fernando Sanchez-Alonso², Javier Manero³, Ana M. Ortiz Garcia⁴, Eva Pérez-Pampin⁵, Rosa Roselló⁶, Carlos Rodriguez-Lozano⁷, Raimon Sanmarti¹, Juan J. Gómez-Reino⁵ and BIOBADASER 2.0 Study Group, ¹Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, ²Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ³Rheumatology, Hospital Miguel Servet, Zaragoza, Spain, ⁴Rheumatology, Rheumatology Service, Hospital Universitario de La Princesa, IIS-IP, Madrid, Spain, ⁵Rheumatology, Hospital Clínico Universitario. Santiago de Compostela, Santiago de Compostela, Spain, ⁶Rheumatology, H San Jorge, Huesca, Spain, ⁷Rheumatology, Hospital de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain
Background/Purpose: Currently, the most widely used biological agents for rheumatoid arthritis (RA) patients are the inhibitors of the tumor necrosis factor (TNFi), although other biological…
Abstract Number: 2553 • 2016 ACR/ARHP Annual Meeting
Pregnancy Outcomes in Patients with Rheumatoid Arthritis Treated with Abatacept – Review of a Safety Database
H Yu, K Angelini, A Dominique and TA Simon, Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: Women are affected by RA 3–4 times more often than men. RA treatment choice during pregnancy can be a challenge for women to minimize…
Abstract Number: 630 • 2016 ACR/ARHP Annual Meeting
Strategies for Biological Drug Quantification in Biological Drug Immune Responses
Michael Kruse Meyer^1,2, Marlene Andersen^1,3, Troels Vindbæk Stausbo⁴, Tue Bjerg Bennike^4,5, Grethe Neumann Andersen^1,6 and Allan Stensballe^3,4, ¹Department of Rheumatology, North Denmark Regional Hospital, Hjørring, Denmark, ²Laboratory for Medical Mass Spectrometry, Aalborg University, Aalborg, Denmark, ³Department of Health Science and Technology, Aalborg University, Aalborg, Denmark, ⁴Laboratory of Medical Mass Spectrometry, Aalborg University, Aalborg, Denmark, ⁵Research Unit for Molecular Diagnostic and Clinical Research, Harvard Medical School, Boston, MA, ⁶Center for Clinical Science, Aalborg University, Hjørring, Denmark
Background/Purpose: The development of the biological DMARDs has benefitted patients, who previously had no treatment options. Currently no method for stratifying patients to these drugs…
Abstract Number: 2583 • 2016 ACR/ARHP Annual Meeting
Abatacept in Rheumatoid Arthritis with Interstitial Lung Disease: A Multicenter Study of 55 Patients
Carlos Fernández-Díaz¹, Javier Loricera¹, Santos Castañeda², Clara Ojeda-Garcia³, Alejandro Olivé⁴, Patricia E. Carreira⁵, Trinidad Perez Sandoval⁶, Miriam Retuerto⁷, Evelin Cecilia Cervantes Pérez⁸, Samantha Rodriguez-Muguruza⁴, Bryan Josue Robles Flores⁹, Blanca Hernández-Cruz¹⁰, Ana Urruticoechea¹¹, O. Maiz Alonso¹², Desiree Palma¹³, Luis Arboleya¹⁴, Gema Bonilla¹⁵, Íñigo Hernández-Rodríguez¹⁶, Concepción Delgado¹⁷, Rosa Expósito Molinero¹⁸, Ana Ruibal Escribano¹⁹, Juan Blanco Madrigal²⁰, José Antonio Bernal²¹, Manuel Rodríguez-Gómez²², Paloma Vela Casasempere²³, Belen Alvarez-Rodriguez²⁴, María Concepción Fito Manteca²⁵, Francisco Ortiz Sanjuan²⁶, Javier Narváez²⁷, Manuel Jose Moreno²⁸, Mireia Lopez-corbeto²⁹, Natalia Mena-Vazquez³⁰, Lucia C. Domínguez-Casas¹, Clara Aguilera-Cros³¹, Victor Mora-Cuesta³², Natalia Palmou-Fontana¹, Miguel Angel Gonzalez-Gay³³, José Luis Hernandez³⁴ and Ricardo Blanco¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ²Rheumatology, Hospital de la Princesa, IIS-IP, Madrid, Spain, ³Rheumatology, Hospital Virgen de la Macarena, Sevilla, Spain, ⁴Rheumatology, Hospital Universitario Germans Trias i Pujol, Barcelona, Spain, ⁵Multidisciplinary Pulmonary Hypertension Unit. Hospital Universitario 12 de Octubre, Madrid, Spain, ⁶Rheumatology, Hospital de León, LEÓN, Spain, ⁷Rheumatology, Hospital de Leon, Leon, Spain, ⁸Rheumatology, Hospital Santiago de Compostela, Santiago de Compostela, Spain, ⁹Rheumatology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, ¹⁰Rheumatology, Hospital Universitario Virgen Macarena, Sevilla, Spain, ¹¹Hospital Can Misses, Ibiza, Spain, ¹²Rheumatology, Hospital Donostia, San Sebastian, Spain, ¹³Rheumatology, Rafael Mendez Hospital, Spain., Lorca (Murcia), Spain, ¹⁴Rheumatology, Hospital Universitario Central de Asturias, Oviedo, Spain, ¹⁵Rheumatology, Hospital La Paz - IdiPaz, Madrid, Spain, ¹⁶Rheumatology, CHUVI Vigo, Vigo, Spain, ¹⁷Rheumatology, Hospital Clinico Universitario Lozano Blesa, zaragoza, Spain, ¹⁸Rheumatology, Hospital Comarcal de Laredo. Spain, Laredo, Spain, ¹⁹Rheumatology, Hospital Universitario de Araba, Vittoria, Spain, ²⁰Rheumatology, Hospital de Basurto, BIlbao, Spain, ²¹Sección de Reumatología, Hospital General de Alicante, Alicante, Spain, ²²Complejo Hospitalario Universitario de Ourense, Ourense, Spain, ²³Rheumatology, Hospital General de Alicante, Alicante, Spain, ²⁴Hospital Txagorritxu, Vittoria, Spain, ²⁵Reumatología, Hospital de Navarra, Pamplona, Spain, ²⁶Rheumatology, Hospital La Fe, Valencia, Spain, ²⁷Rheumatology Department, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Spain, ²⁸Rheumatology, Hospital Virgen de la Arrixaca, MURCIA, Spain, ²⁹Hospital Universitario Vall d'Hebron, Barcelona, Spain, ³⁰Rheumatology, Hospital Universitario de Malaga, Malaga, Spain, ³¹Rheumatology, Hospital Virgen del Rocio, Sevilla, Spain, ³²Neumology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ³³Department of RheumaRheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ³⁴Internal Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain
Background/Purpose: Interstitial Lung Disease (ILD) is a severe extra-articular manifestation of rheumatoid arthritis (RA). A potential association of anti-TNFα drugs and conventional disease-modifying anti-rheumatic drugs…
Abstract Number: 948 • 2016 ACR/ARHP Annual Meeting
Subcutaneous Abatacept in Patients with Polyarticular-Course Juvenile Idiopathic Arthritis and Inadequate Response to Biologic or Non-Biologic Disease-Modifying Antirheumatic Drugs: Pharmacokinetics, Efficacy and Safety
DJ Lovell¹, N Ruperto², N Tzaribachev³, G Vega-Cornejo⁴, I Louw⁵, A Berman^6,7, I Calvo⁸, R Cuttica⁹, G Horneff¹⁰, F Avila-Zapata¹¹, J Anton¹², R Cimaz¹³, E Solau-Gervais¹⁴, R Joos¹⁵, G Espada¹⁶, X Li¹⁷, M Nys¹⁸, R Wong¹⁷, S Banerjee¹⁷, Hermine I. Brunner¹⁹, A Martini²⁰ and For Pediatric Rheumatology International Trials Organization (PRINTO)/Pediatric Rheumatology Collaborative Study Group (PRCSG), ¹Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Istituto G. Gaslini Pediatria II Reumatologia, Genoa, Italy, ³Pediatric Rheumatology, Bad Bramstedt, Germany, ⁴Clinica de Rheumatología y Enfermedades Autoinmunes (CREA), Hospital México Americano, Guadalajara Jalisco, Mexico, ⁵Panorama Medical Centre, Cape Town, South Africa, ⁶Universidad Nacional de Tucuman and Centro Médico Privado de Reumatología, Tucumán, Argentina, ⁷Universidad Nacional de Tucuman and Centro Médico Privado de Reumatología, Tucuman, Argentina, ⁸Hospital Univ. La Fe, Valencia, Spain, ⁹Hospital General de Niños Pedro de Elizalde, Buenos Aires, Argentina, ¹⁰Centre Paediatric Rheumatology, Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ¹¹Star Medica Hospital, Merida, Mexico, ¹²Unitat de Reumatologia Pediàtrica, Hospital Sant Joan de Déu, Barcelona, Spain, ¹³Pediatrics, Ospedale Pediatrico Anna Meyer, Florence, Italy, ¹⁴Hôpital de la Miletrie, Poitiers, France, ¹⁵University Hospital Gent, Gent, Belgium, ¹⁶Cramer 1853 4°C, Hospital de Ninos Dr Ricardo Gutierrez, Buenos Aires, Argentina, ¹⁷Bristol-Myers Squibb, Princeton, NJ, ¹⁸Bristol-Myers Squibb, Braine-l’Alleud, Belgium, ¹⁹Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²⁰Istituto G. Gaslini Pediatria II Reumatologia and University of Genova, Genoa, Italy
Background/Purpose: IV abatacept (ABA) 10 mg/kg every 4 weeks was well tolerated and effective in reducing the signs and symptoms of polyarticular-course juvenile idiopathic arthritis…
Abstract Number: 2613 • 2016 ACR/ARHP Annual Meeting
Seropositivity for RF or ACPA Predicts Long Term Drug Retention with Rituximab, but Not with Abatacept and Tocilizumab : Long-Term Registry Data in 4498 Patients with Rheumatoid Arthritis
Jacques-Eric Gottenberg¹, Jacques Morel², Arnaud Constantin³, Thomas Bardin⁴, Alain G. Cantagrel⁵, Bernard Combe⁶, Maxime Dougados⁷, Rene-Marc Flipo⁸, Alain Saraux⁹, Thierry Schaeverbeke¹⁰, Jean Sibilia¹¹, Martin Soubrier¹², Olivier Vittecoq¹³, Elodie Perrodeau¹⁴, Philippe Ravaud¹⁵, Xavier Mariette¹⁶ and on behalf of the French Society of Rheumatology and of all the investigators participating to the AIR, ORA and REGATE registries, ¹Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ²Rheumatology, Department of Rheumatology, Montpellier University Hospital, Montpellier, France, ³Rheumatology, CHU Purpan - Hopital Pierre-Paul Riquet, Toulouse, France, ⁴Clinique de Rhumatologie, Hopital Lariboisiere, Paris Cedex 10, France, ⁵Rheumatology, Centre Hospitalier Universitaire, Toulouse Purpan, Toulouse, France, ⁶Département Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ⁷Rheumatology, Paris Descartes University, Paris, France, ⁸Rheumatology, University Hospital, Lille, France, ⁹Rheumatology, Brest University Hospital, Brest, France, ¹⁰Rheumatology, CHU Bordeaux, Bordeaux, France, ¹¹Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ¹²Rheumatology, Department of Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, ¹³Rheumatology, Rouen University Hospital &INSERM U905, Rouen, France, ¹⁴Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ¹⁵Epidemiologist, PARIS, France, ¹⁶Rheumatology, Rheumatology department, Bicetre Hospital, Paris-Sud University, Le Kremlin Bicetre, France
Background/Purpose: Seropositivity for RF or ACPA is associated with a better short-term effectiveness and drug retention of abatacept (ABA) and rituximab (RTX). Data are very…
Abstract Number: 979 • 2016 ACR/ARHP Annual Meeting
A Randomized Double-Blind Trial of Abatacept and Glucocorticoids for the Treatment of Takayasu’s Arteritis
Carol A. Langford¹, David Cuthbertson², Steven R. Ytterberg³, Nader A. Khalidi⁴, Paul A. Monach⁵, Simon Carette⁶, Philip Seo⁷, Larry W. Moreland⁸, Michael Weisman⁹, Curry L. Koening¹⁰, Antoine G. Sreih¹¹, Robert F. Spiera¹², Carol A McAlear¹³, Kenneth J. Warrington³, Christian Pagnoux¹⁴, Kathleen Maksimowicz-McKinnon¹⁵, Lindsy J. Forbess⁹, Gary S. Hoffman¹⁶, Renee Borchin¹⁷, Jeffrey Krischer¹⁷ and Peter A. Merkel¹⁸, ¹Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ²Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ³Rheumatology, Mayo Clinic, Rochester, MN, ⁴McMaster University, St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁵Rheumatology, Boston University School of Medicine, Boston, MA, ⁶Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁷Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ⁸Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁹Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁰Rheumatology, University of Utah, Salt Lake City, UT, ¹¹Department of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹²Hospital for Special Surgery, Cornell, New York, NY, ¹³Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹⁴Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ¹⁵Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹⁶Rheumatology, Cleveland Clinic, Cleveland, OH, ¹⁷University of South Florida, Tampa, FL, ¹⁸Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Takayasu’s arteritis (TAK) is a large-vessel primary systemic vasculitis that affects the aorta, its branches, and the pulmonary arteries. Despite treatment with glucocorticoids, relapse…
Abstract Number: 2614 • 2016 ACR/ARHP Annual Meeting
Similar Rates of Death, Serious Infections, Cancers, Major Cardiovascular Events in Patients Treated with Abatacept, Rituximab and Tocilizumab: Long-Term Registry Data in 4498 Patients with Rheumatoid Arthritis
Jacques-Eric Gottenberg¹, Jacques Morel^2,3, Arnaud Constantin⁴, Thomas Bardin⁵, Alain Cantagrel^6,7, Bernard Combe⁸, Maxime Dougados^9,10, Rene-Marc Flipo¹¹, Alain Saraux¹², Thierry Schaeverbeke¹³, Jean Sibilia¹⁴, Martin Soubrier¹⁵, Olivier Vittecoq¹⁶, Elodie Perrodeau¹⁷, Philippe Ravaud¹⁸, Xavier Mariette¹⁹ and on behalf of the French Society of Rheumatology and of all the investigators participating to the AIR, ORA and REGATE registries, ¹Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ²Rheumatology, Department of Rheumatology, Montpellier University Hospital, Montpellier, France, ³Immuno-Rheumatology, University Hospital of Lapeyronie, University Montpellier 1, Montpellier, France, ⁴Rheumatology, CHU Purpan - Hopital Pierre-Paul Riquet, Toulouse, France, ⁵Service de Rhumatologie. Centre Viggo Petersen. Hôpital Lariboisière, Paris, France, ⁶Rheumatology, INSERM CNRS UMR 1043, Paul Sabatier University Toulouse, Purpan Teaching Hospital, Toulouse, France, ⁷Rheumatology, Purpan University Hospital, Toulouse Cedex 9, France, ⁸Département Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ⁹Rheumatology, Paris Descartes University, Paris, France, ¹⁰René Descartes University and Hôpital Cochin, Paris, France, ¹¹Rheumatology, Hopital R Salengro CHRU, Lille, France, ¹²Rheumatology, Brest University Hospital, Brest, France, ¹³Rheumatology, CHU Bordeaux, Bordeaux, France, ¹⁴Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ¹⁵Rheumatology, Department of Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, ¹⁶Rheumatology, Rouen University Hospital &INSERM U905, Rouen, France, ¹⁷Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ¹⁸Epidemiology, Hotel Dieu, PARIS, France, ¹⁹Rheumatology, Rheumatology department, Bicetre Hospital, Paris-Sud University, Le Kremlin Bicetre, France
Background/Purpose: Assessment of safety in randomized controlled trials is limited by trial durations, and selection of patients with few or now comorbidities. Such limitations can…
Abstract Number: 1041 • 2016 ACR/ARHP Annual Meeting
Abatacept in the Treatment of Active Psoriatic Arthritis: 24-Week Results from a Phase III Study
P Mease¹, AB Gottlieb², D van der Heijde³, Oliver FitzGerald⁴, A Johnsen⁵, M Nys⁶, S Banerjee⁵ and D Gladman⁷, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Tufts University School of Medicine (affiliation at the time of the study), Boston, MA, ³Leiden University Medical Center, Leiden, Netherlands, ⁴Department of Rheumatology, St Vincent’s University Hospital and University College Dublin, Dublin, Ireland, ⁵Bristol-Myers Squibb, Princeton, NJ, ⁶Bristol-Myers Squibb, Braine-l’Alleud, Belgium, ⁷Rheumatology, University of Toronto and Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Abatacept (ABA), a selective T-cell co-stimulation modulator, showed promise for the treatment of PsA in a Phase II trial.1 This prompted the conduct of…
Abstract Number: 2628 • 2016 ACR/ARHP Annual Meeting
Retention of Use and Safety of Subcutaneous Abatacept in Rheumatoid Arthritis: A Patient Record Assessment in a Compassionate Use Programme in South Africa, a Tuberculosis Endemic Country
I Louw¹, M Ally², DC Janse van Rensburg², E Van Duuren³, D Nel³, H Miller-Janson⁴, M de Necker⁴, JC de Beer⁴ and H Duvenhage⁵, ¹Panorama Medical Centre, Cape Town, South Africa, ²University of Pretoria, Pretoria, South Africa, ³Jacaranda Hospital, Pretoria, South Africa, ⁴HEXOR (PTY) Ltd, Pretoria, South Africa, ⁵Bristol-Myers Squibb, Johannesburg, South Africa
Background/Purpose: South Africa is a tuberculosis (TB) endemic country having one of the highest TB infection rates in the world with close to 1000 cases…
Abstract Number: 1565 • 2016 ACR/ARHP Annual Meeting
Gene Modules Correlated with Disease Activity and Abatacept Treatment Identified with Weighted Gene Co-Expression Network Analysis of CD4+ T Cell Subsets of RA
Shuji Sumitomo¹, Yasuo Nagafuchi¹, Yumi Tsuchida¹, Haruka Tsuchiya¹, Mineto Ota¹, Kazuyoshi ishigaki², Shinichiro Nakachi¹, Rika Kato¹, Keiichi Sakurai¹, Norio Hanata¹, Shoko Tateishi³, Hiroko Kanda³, Akari Suzuki⁴, Yuta Kochi⁴, Keishi Fujio¹ and Kazuhiko Yamamoto¹, ¹Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ²Laboratory for Statistical Analysis, Center for Integrative Medical Sciences, The Institute of Physical and Chemical Research (RIKEN), Yokohama, Japan, ³Department of Immunotherapy Management, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ⁴Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan
Background/Purpose: Although there are several reports of transcriptome analysis of peripheral blood mononuclear cells (PBMC) in RA, analysis of detailed CD4+ subset and the effect…
Abstract Number: 9L • 2015 ACR/ARHP Annual Meeting
A Randomized Double-Blind Trial of Abatacept and Glucocorticoids for the Treatment of Giant Cell Arteritis
Carol A. Langford¹, David Cuthbertson², Steven R. Ytterberg³, Nader A. Khalidi⁴, Paul A. Monach⁵, Simon Carette⁶, Philip Seo⁷, Larry W. Moreland⁸, Michael Weisman⁹, Curry L. Koening¹⁰, Antoine G. Sreih¹¹, Robert F. Spiera¹², Carol McAlear¹³, Kenneth J. Warrington¹⁴, Christian Pagnoux⁶, Kathleen Maksimowicz-McKinnon¹⁵, Lindsy J. Forbess¹⁶, Gary S. Hoffman¹, Renee Borchin¹⁷, Jeffrey Krischer¹⁷ and Peter A. Merkel¹⁸, ¹Rheumatology, Cleveland Clinic, Cleveland, OH, ²Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ³Rheumatology Division, Mayo Clinic, Rochester, MN, ⁴McMaster University, St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁵Rheumatology, Boston University School of Medicine, Boston, MA, ⁶Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁷Division of Rheumatology, Johns Hopkins, Baltimore, MD, ⁸Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁹Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁰Division of rheumatology, George E. Wahlen Department of Veterans Affairs Medical Center Salt Lake City and University of Utah, University of Utah School of Medicine, Salt Lake City, UT, ¹¹Department of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹²Rheumatology, Hospital for Special Surgery, New York, NY, ¹³Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹⁴Rheumatology, Mayo Clinic, Rochester, MN, ¹⁵Rheumatology, University of Pittsburgh, Pittsburgh, PA, ¹⁶Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁷University of South Florida, Tampa, FL, ¹⁸Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Giant cell arteritis (GCA) is a large-vessel primary systemic vasculitis. Although glucocorticoids are effective in treating GCA, they are associated with substantial toxicity and…
Abstract Number: 458 • 2015 ACR/ARHP Annual Meeting
First Year Canadian Experience with Subcutaneous Abatacept in Routine Practice for the Treatment of Patients with Rheumatoid Arthritis: Data from the Orencia Response Program (ORP) Network
Boulos Haraoui¹, Louis Coupal², Radmila Day³, Lionel Budry⁴ and Youb Chalabi⁵, ¹Institut de Rhumatologie de Montréal and University of Montreal, Montreal, QC, Canada, ²Rheumatology, Institut de recherche en rhumatologie de Montréal (IRRM), Montréal, QC, Canada, ³None, Montreal, QC, Canada, ⁴Bristol Myers Squibb Canada, St-Laurent, QC, Canada, ⁵Bristol Myers Squibb, Montreal, QC, Canada
Background/Purpose: The subcutaneous (SC) formulation of abatacept (ABA) has been available in Canada since January 2014. Here we report first year experience with SC ABA…
Abstract Number: 2668 • 2015 ACR/ARHP Annual Meeting
Effect of Anti-Cyclic Citrullinated Peptide 2 Immunoglobulin M Serostatus on Efficacy Outcomes Following Treatment with Abatacept Plus Methotrexate
T. W. J. Huizinga¹, SE Connolly², A Johnsen², J Zhu², Daniel E. Furst³, VP Bykerk⁴, Gerd Burmester⁵, BG Combe⁶, DA Wong², LA Trouw¹, René E. M. Toes¹ and Paul Emery⁷, ¹Leiden University Medical Center, Leiden, Netherlands, ²Bristol-Myers Squibb, Princeton, NJ, ³Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁴Weill Cornell Medical College, New York, NY, ⁵Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁶Montpellier University, Montpellier, France, ⁷University of Leeds, Leeds, United Kingdom
Background/Purpose: Anti-citrullinated protein antibodies (ACPA) are a marker of RA, and the presence of the immunoglobulin M (IgM) isotype indicates an ongoing immune response involving…
Abstract Number: 459 • 2015 ACR/ARHP Annual Meeting
The Effect of Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Positivity on Drug Survival of Abatacept in Patients with Rheumatoid Arthritis in Routine Care: The Results from Turkbio Registry
Ihsan Ertenli¹, Omer Karadag¹, Yavuz Pehlivan², Ediz Dalkilic³, Ahmet Mesut Onat⁴, Bunyamin Kisacik⁵, Gercek Can⁶, Servet Akar⁷, Sedat Capar⁸, Umut Kalyoncu¹, Mustafa Ferhat Oksuz⁹, Emine Figen Tarhan⁷ and Nurullah Akkoc⁶, ¹Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ²Department of Rheumatology, Uludag University Faculty of Medicine, Bursa, Turkey, ³Department of Rhematology, Uludag University Faculty of Medicine, Bursa, Turkey, ⁴Rheumatology, Gaziantep University School of Medicine, Gaziantep, Turkey, ⁵Rheumatology Department, Gaziantep University School of Medicine, Gaziantep, Turkey, ⁶Department of Rheumatology, Dokuz Eylul University, Faculty of Medicine, Izmir, Turkey, ⁷Department of Internal Medicine, Division of Rheumatology, Izmir Katip Celebi University School of Medicine, Izmir, Turkey, ⁸Dokuz Eylül University Faculty of Statistics, Izmir, Turkey, ⁹Rheumatology, Uludag University Faculty of Medicine, Bursa, Turkey
Background/Purpose: Abatacept (ABA) is a biological anti-rheumatic drug used in Rheumatoid Arthritis (RA). In TURKBIO, Turkish Biologic Registry, data on patient characteristics, diagnosis, previous treatment…

« Previous Page
1
…
4
5
6
7
8
…
12
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].